Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Alberici

Showing results (1-10 of 124) with videos related to

Pageof 13
Sort By:
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|February 18, 2021
[State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy]Martina Uzzo, Federico Alberici
Rheumatology (Oxford, England)|December 28, 2018
Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer?Matthias A Cassia, Federico Alberici
Annals of the Rheumatic Diseases|May 29, 2021
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'Chiara Salviani, Francesco Scolari, Federico Alberici
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 16, 2013
Impact of rituximab trials on the treatment of ANCA-associated vasculitisFederico Alberici, David R W Jayne
Kidney International Reports|August 11, 2020
The Authors ReplyFederico Alberici, Elisa Delbarba, Francesco Scolari
Rheumatology (Oxford, England)|April 21, 2023
The paradigm shift in ANCA-associated vasculitis: prime time for the complement targetingLuca Quartuccio, Elena Treppo, Federico Alberici
Clinical Kidney Journal|September 5, 2023
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximabFederico Alberici, Federica Mescia, Francesco Scolari
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 20, 2014
Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitisFederico Alberici, Davide Martorana, Augusto Vaglio
Frontiers in Immunology|December 7, 2020
Editorial: "Toward Precision Medicine in Vasculitis"Federico Alberici, Giacomo Emmi, Andreas Kronbichler
Kidney International Reports|May 25, 2026
Response to the Letter to the Editor entitled "Kidney Outcomes With Rituximab Versus Cyclophosphamide in Crescentic ANCA-Associated Glomerulonephritis: Contextualizing Observational Findings"Federica Mescia, Martina Uzzo, Federico Alberici
Pageof 13

Showing results (1-10 of 124) with videos related to

Sort By:
Pageof 13
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|February 18, 2021
[State of art and new perspectives in the induction regimen of ANCA-associated vasculitis with renal involvement: from histopathology to therapy]Martina Uzzo, Federico Alberici
Rheumatology (Oxford, England)|December 28, 2018
Prevention of arterial thrombosis recurrence in anti-phospholipid syndrome: are anti-platelets the answer?Matthias A Cassia, Federico Alberici
Annals of the Rheumatic Diseases|May 29, 2021
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'Chiara Salviani, Francesco Scolari, Federico Alberici
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 16, 2013
Impact of rituximab trials on the treatment of ANCA-associated vasculitisFederico Alberici, David R W Jayne
Kidney International Reports|August 11, 2020
The Authors ReplyFederico Alberici, Elisa Delbarba, Francesco Scolari
Rheumatology (Oxford, England)|April 21, 2023
The paradigm shift in ANCA-associated vasculitis: prime time for the complement targetingLuca Quartuccio, Elena Treppo, Federico Alberici
Clinical Kidney Journal|September 5, 2023
The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximabFederico Alberici, Federica Mescia, Francesco Scolari
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 20, 2014
Genetic aspects of anti-neutrophil cytoplasmic antibody-associated vasculitisFederico Alberici, Davide Martorana, Augusto Vaglio
Frontiers in Immunology|December 7, 2020
Editorial: "Toward Precision Medicine in Vasculitis"Federico Alberici, Giacomo Emmi, Andreas Kronbichler
Kidney International Reports|May 25, 2026
Response to the Letter to the Editor entitled "Kidney Outcomes With Rituximab Versus Cyclophosphamide in Crescentic ANCA-Associated Glomerulonephritis: Contextualizing Observational Findings"Federica Mescia, Martina Uzzo, Federico Alberici
Pageof 13